COVID-19 VACCINATION
CURRENTLY ENROLLING TRIALS

The study is designed with two principal aims: First, to estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech COVID-19 Vaccinein a High-Allergy/Mast Cell Disorder (HA/MCD) population. Second, if the risk in the HA/MCD is demonstrable, to determine whether the proportions are higher in the HA/MCD compared to a non-atopic population.

​

Open for participants age 5 to 17 who have NOT received any dose of a COVID-19 vaccine and meet at least one of the criteria below:

​

• History of a severe allergic reaction to food(s), allergen immunotherapy, or insect venom(s) with use of epinephrine OR visit to the emergency room within the last 15 years

• History of documented, immediate allergic reactions to 2 or more unrelated drugs within the last 15 years

• A convincing clinical history, or a history that is accompanied by a positive skin test, of an immediate reaction to a drug or vaccine within the last 5 years

• History of a physician-diagnosed mast cell disorder (e.g., mastocytosis, mast cell activation syndrome, or hereditary alpha-tryptasemia).

OR

• No history of any allergies or other atopic conditions such as atopic dermatitis (eczema).

 

Further inclusion/exclusion criteria may apply.

​

Click here for more information about the study.